Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Lonza Group AG is a leading global provider of integrated solutions for the pharmaceutical and biotechnology industries, specializing in contract development and manufacturing. The company operates in Europe, North America, and Asia, with key facilities in Switzerland and the U.S., focusing on biologics, cell and gene therapies, and small molecules.
Lonza generates revenue primarily through contract manufacturing services for pharmaceutical companies, leveraging its advanced biomanufacturing capabilities and regulatory expertise. The company benefits from high barriers to entry due to stringent regulatory requirements and significant capital investments in production facilities.
Regulatory approvals for new therapies that Lonza is contracted to produce
Changes in demand for biologics and cell therapies driven by market trends
Partnership announcements with major pharmaceutical companies
Capacity expansions or new facility openings
Regulatory changes that could impact manufacturing processes or approval timelines
Technological disruption in biomanufacturing techniques
Increased competition from emerging biomanufacturers in Asia
Potential loss of contracts to larger players with more extensive resources
Moderate debt levels could pose risks if cash flows do not improve as expected
Liquidity risks associated with negative free cash flow
moderate - Lonza's business is somewhat insulated from economic cycles due to the essential nature of healthcare spending, but demand for certain therapies can fluctuate with economic conditions.
Higher interest rates could increase financing costs for capital expenditures, impacting expansion plans. However, the demand for healthcare services tends to remain stable, mitigating some effects on valuation multiples.
minimal - Lonza's operations are not heavily reliant on credit markets, and its debt levels are manageable.
growth - Lonza's focus on high-growth areas such as cell and gene therapies attracts growth-oriented investors.
moderate - The stock has shown some volatility, particularly in response to earnings reports and regulatory news.
